The NICE guideline CG181 includes recommendations on risk assessment for CVD and on the use of
lipid-lowering drugs. The original guideline is updated in part to allow consideration of new
evidence on risk assessment tools and to reflect changes in price and availability of generic statins.
NICE has produced guidance on other modifiable risk factors for CVD and this guideline should be
used in conjunction with it. You can review guidance on other risk factors here and here.
“We’ve come a long way, but cardiovascular disease (CVD) still causes a quarter of all deaths in the UK, and it remains a major driver of health inequalities. But it doesn’t have to be this way. Cardiovascular health is determined in part by a range of modifiable factors. So, by focusing on CVD prevention, we have a tangible opportunity to close the health gap. We can do this in 2 ways. First by reducing the risk of developing CVD for millions more people with population-level interventions to create a healthy environment. And second, by detecting, diagnosing, and effectively managing high-risk conditions as early as possible to help prevent acute cardiovascular events and associated long-term conditions.”
John Maingay - Director
of Policy and
Influencing
at the
British Heart
Foundation
You can read more from the NICE Impact Report on CVD Prevention here.
